DUBLIN—-Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer’s disease patients as measured using a neuroimaging technique known as [11C ]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology.

The rest is here:
Neuroimaging Technique Supports Reduction in Amyloid-Beta in Brains of Patients Suffering from Alzheimer’s Disease … (Business Wire via Yahoo! Finance)